Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached

por Breccia, Massimo
Publicado 2020

American Society of Hematology 2020 Podcast Collection: CML

por Breccia, Massimo
Publicado 2021

American Society of Hematology 2020 Podcast Collection: MPN

por Breccia, Massimo
Publicado 2021

Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments

por Breccia, Massimo
Publicado 2022

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib

por Breccia, Massimo, Alimena, Giuliana
Publicado 2008

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs

por Breccia, Massimo, Alimena, Giuliana
Publicado 2014

Bosutinib for Chronic Myeloid Leukemia

por Breccia, Massimo, Binotto, Gianni
Publicado 2015

Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia

por De Angelis, Federico, Breccia, Massimo
Publicado 2015

Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia

por Molica, Matteo, Abruzzese, Elisabetta, Breccia, Massimo
Publicado 2020

Management of Acute Promyelocytic Leukemia in the Elderly

por Lo-Coco, Francesco, Latagliata, Roberto, Breccia, Massimo
Publicado 2013

Systematic review of dasatinib in chronic myeloid leukemia

por Breccia, Massimo, Salaroli, Adriano, Molica, Matteo, Alimena, Giuliana
Publicado 2013

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge

por Iurlo, Alessandra, Cattaneo, Daniele, Bucelli, Cristina, Breccia, Massimo
Publicado 2021

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios

por Palandri, Francesca, Breccia, Massimo, De Stefano, Valerio, Passamonti, Francesco
Publicado 2021

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib

por Breccia, Massimo, Colafigli, Gioia, Quattrocchi, Luisa, Abruzzese, Elisabetta, Alimena, Giuliana
Publicado 2016

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia

por Molica, Matteo, Scalzulli, Emilia, Colafigli, Gioia, Foà, Robin, Breccia, Massimo
Publicado 2019

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia

por Breccia, Massimo, Abruzzese, Elisabetta, Annunziata, Mario, Luciano, Luigia, Sica, Simona
Publicado 2021

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

por Castagnetti, Fausto, Pane, Fabrizio, Rosti, Gianantonio, Saglio, Giuseppe, Breccia, Massimo
Publicado 2021

Editorial: Risk-stratification in myelodysplastic syndromes

por Breccia, Massimo, Vinchi, Francesca, Bonifacio, Massimiliano, Binotto, Gianni, Zheng, Gang
Publicado 2022

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review

por Tiribelli, Mario, Palandri, Francesca, Sant’Antonio, Emanuela, Breccia, Massimo, Bonifacio, Massimiliano
Publicado 2019

Eine klinische Perspektive auf die Behandlung von chronischer myeloischer Leukämie in der chronischen Phase

por García-Gutiérrez, Valentin, Breccia, Massimo, Jabbour, Elias, Mauro, Michael, Cortes, Jorge E.
Publicado 2023